BMS-986308 is a selective, orally active renal outer medullary potassium (ROMK) channel inhibitor. It demonstrates greater selectivity for ROMK over hERG channels and is applicable in heart failure research.

BMS-986308（0.01-3 mg/kg; 口服; 一次）在容量负荷大鼠的利尿模型中显示出显著疗效 [1]。动物模型：雄性Sprague-Dawley大鼠（年龄：8-12周，体重270-300 g）[1]。剂量：0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg和3 mg/kg。给药方式：口服一次（10% v/v DMAC，40% v/v PEG400，50% v/v的30% w/v HPβCD于50 mM柠檬酸缓冲液（pH 4.0）中）。结果：显著增加利尿作用。